The US Patent and Trademark Office (USPTO) has granted a patent for Axcella Therapeutics’ long Covid treatment candidate AXA1125. AXA1125 is a novel composition of endogenous metabolic modulators (EMMs) designed to simultaneously support metabolic, inflammatory and fibrotic pathways associated with fatigue. In April, The Lancet published the results of Axcella’s Phase IIa trial, which showed […]